News & Updates

Show Multimedia Only

Real-world data back CV safety of JAK inhibitors

28 Jun 2023 by

Two real-world studies presented at EULAR 2023 reflected the cardiovascular (CV) safety of Janus kinase inhibitors (JAKi*) in patients with rheumatoid arthritis (RA).

28 Jun 2023

$Uricase-based combo therapy promising for refractory gout$

Uricase-based combo therapy promising for refractory gout

28 Jun 2023 by

Half of gout patients receiving novel uricase analogue infusions, along with a proprietary rapamycin formulation, got their serum urate controlled in two phase III studies presented at EULAR 2023.

28 Jun 2023

SGLT2 inhibitors score big, this time in gout

22 Jun 2023 by

Patients initiated on gliflozins or flozins – also called sodium-glucose co-transporter 2 (SGLT2) inhibitors – for type 2 diabetes (T2D) who were previously on metformin had reductions in the incidents of gout of up to 60 percent compared with other second-line agents in a recent study.

22 Jun 2023

Novel drug STRIDES in the right direction for knee OA

21 Jun 2023 by

In the phase III STRIDES X-Ray Extension study, additional doses of the investigational CLK/DYRK inhibitor lorecivivint delivered favourable outcomes for individuals with advanced knee osteoarthritis (OA).

21 Jun 2023

Dazodalibep reduces Sjögren’s syndrome-related symptoms

21 Jun 2023 by

Treatment with dazodalibep, a novel nonantibody fusion protein that acts as an antagonist of CD40 ligand, significantly reduced symptom burden in adults with Sjögren’s syndrome, according to the ALISS trial presented at EULAR 2023.

21 Jun 2023

Romosozumab one-ups denosumab in boosting bone mineral density for chronic steroid users

20 Jun 2023 by

In the treatment of chronic glucocorticoid users with high fracture risk, romosozumab yields higher gains in spine bone mineral density (BMD) compared with denosumab, as shown in a pilot trial presented at EULAR 2023.

20 Jun 2023

AI predicts early-stage rheumatoid arthritis using MRI scans

20 Jun 2023 by

It is now possible to predict rheumatoid arthritis (RA), thanks to interpretations of magnetic resonance imaging (MRI) scans made by an artificial intelligence (AI) model.

20 Jun 2023

Abatacept halts RA progression early in high-risk group

20 Jun 2023 by

Treatment with abatacept for a year halts disease progression in high-risk patients presenting with signs of imminent onset of rheumatoid arthritis (RA) in the phase IIb APIPPRA trial.

20 Jun 2023

Dual-target oral drug outperforms tofacitinib in RA treatment

19 Jun 2023 by

The novel, highly selective dual JAK1/TYK2 inhibitor TLL-018 appears to have better efficacy than the currently approved JAK inhibitor tofacitinib in the treatment of patients with rheumatoid arthritis (RA), according to the results of a head-to-head trial presented at EULAR 2023.

19 Jun 2023

Secukinumab on par with adalimumab biosimilar in r-axSpA

19 Jun 2023 by

Treatment with secukinumab (SEC) shows no significant difference with adalimumab biosimilar (SDZ-ADL) in spinal radiographic progression, which remains low over 2 years, among patients with radiographic axial spondyloarthritis (r-axSpA), according to a phase IIIb study presented at EULAR 2023.

19 Jun 2023

News & Updates

Showing Rheumatology articles

Showing

Specialty:

Real-world data back CV safety of JAK inhibitors

Uricase-based combo therapy promising for refractory gout

SGLT2 inhibitors score big, this time in gout

Novel drug STRIDES in the right direction for knee OA

Dazodalibep reduces Sjögren’s syndrome-related symptoms

Romosozumab one-ups denosumab in boosting bone mineral density for chronic steroid users

AI predicts early-stage rheumatoid arthritis using MRI scans

Abatacept halts RA progression early in high-risk group

Dual-target oral drug outperforms tofacitinib in RA treatment

Secukinumab on par with adalimumab biosimilar in r-axSpA